Tuberculosis Clinical Trial
Official title:
Phase IV Study of the Quantiferon-RD1 Test
Tuberculosis is still the most common infectious disease in Taiwan. The infants in Taiwan
have been vaccinated at birth with BCG -Tokyo 171 strain since 1951. The BCG vaccination
rate is 97% among first grade students in a recent national survey. Even with such a high
BCG vaccination coverage, Taiwan still has a relatively high TB incidence rate. In 2004,
there were totally 16,784 newly diagnosed TB cases and the annual incidence was 74.11 per
100,000 population nationally. Nearly 70% of the incidence cases were men and 30.4% were
women. The mean age of incidence cases was 57.8 years old (median=63). 8,440(50.29%)
patients were elderly than 65 years old. The elderly men did not receive the BCG vaccination
and were the most important group to develop newly diagnosed tuberculosis and a special
issue for the national TB control program in Taiwan.
The tuberculin skin test (TST) is the only widely available method for detecting whether
people have an immunologic reactivity to mycobacterial antigens and identified as latent
tuberculosis infection (LTBI). Targeted tuberculin testing for latent TB infection is a very
important strategy to identify subjects with high risk to develop tuberculosis including
those who have recent infection with Mycobacterium tuberculosis or have clinical conditions
that associated with an increased risk for progression of LTBI to active TB but the
sensitivity was lower in elderly patients.
Quantiferon-TB gold test (QFT-RD1) is a new diagnostic test for latent tuberculosis and a
valuable alternative to skin testing. This whole-blood assay measures the production of IFN-
in whole blood upon stimulation by ESAT-6 and CFP-10 and allows distinction of latent M.
tuberculosis infection from BCG-induced reactivity. ESAT-6 and CFP-10 are deleted from BCG
Region 1 (RD1), not present in most nontuberculous mycobacteria and are highly specific
indicators of M. tuberculosis infection. Thus, the aim of this study was to estimate the
specificity and sensitivity of a whole blood IFN-γassay employing CFP-10 and ESAT-6, for the
detection of M. tuberculosis infection in a clustered high risk elderly population.
Changhwa Veterans Home is a government-expense veterans home with totally 519 residents in
2004.The inhabitants were all elderly people and lived in groups. , They did not receive BCG
vaccination and were the high risk group to develop endemic TB infection. The annual TB
incidence rate over there was 3,500 per 100,000 population.
STUDY POPULATION AND METHODS Population The study population represented individuals
screened for TB over a 6-month period ending in December 2004 as part of a number of
community health outreach programs based at the Center of Disease Control in Taichung,
Taiwan. Changhwa Veterans Home is a government-expense veterans home with totally 519
residents in 2004. Only individuals with a properly read TST and signed informed consent
were included in the study population. If a TST was positive, further evaluation for TB was
advised. Anyone found to have active TB infection (12 individuals diagnosed, all from
household contacts) was appropriately treated and were also included from the study. No
general population low-risk controls were included in the study population. There were no
other entry exclusions for the study. Before the TST was administered, a short interview
including verbal consent and a BCG scar count evaluation was conducted by an experienced
nurse.
The TST contained 2 tuberculin units (TU) of RT23 tuberculin with Tween 80 (0.2 ml of
1TU/0.1 ml) given intradermally on the left forearm volar surface by Mantoux technique.
Validity measures such as inter-observer performance were done for TST placement or
interpretation individually by two experienced nurse. A purified protein derivative-Siebert
(PPD-S) dose of 5TU is roughly equivalent to the 2TU of RT23. 2TU is the International Union
Against Tuberculosis and Lung Disease recommended dose for RT23 TST. TST was also performed
on BCG-vaccinated health care workers . After 48–72 h of injection, the TST site should be
evaluated for induration and a transverse measurement was recorded. Any readings made
outside of the above time period were excluded from the study. All unvaccinated subjects had
their blood drawn for the QFT-RD1 the same time with applying the first TST. A TST reaction
size of ≧10 mm was interpreted as a ‘positive’ TST which guided any further medical
evaluation. This is the traditional cutoff point used for RT23 tuberculin in Taiwan as well
as in most studies worldwide. If initial TST diameter less than 10 mm, second TST was
repeated within 1-5 weeks to observe any ‘boosting phenomenon’ was possible. Statistical
analysis of skin test results for each population characteristic was done at this cut-off
point, with the exception of one analysis specifically done at≧18 mm in BCG-vaccinated
health care workers.
Household contacts of active TB patients were presumably at highest risk for TB infection;
the group was labeled ‘household contact’. No active TB cases have been reported among these
residents for years.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |